Banca de QUALIFICAÇÃO: LARIZA MARIA DA COSTA

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : LARIZA MARIA DA COSTA
DATE: 22/05/2026
TIME: 08:00
LOCAL: Departamento de Fisioterapia
TITLE:

Survival and the use of non-invasive ventilation in patients with amyotrophic
lateral sclerosis: An observational study in Rio Grande do Norte, Brazil.

 

KEY WORDS:

Pulmonar / Amyotrophic Lateral Sclerosis; Non-Invasive Ventilation; Survival;
Pulmonary Function.

 

PAGES: 46
BIG AREA: Ciências da Saúde
AREA: Fisioterapia e Terapia Ocupacional
SUMMARY:

Introduction: Amyotrophic Lateral Sclerosis (ALS) is a rare neuromuscular
disease characterized by the rapid degeneration of upper and lower motor
neurons and progressive muscle weakness in the spinal, axial, and bulbar
regions. Respiratory function deteriorates as ALS progresses and is
associated with reduced survival. Objectives: The aim of this study was to
evaluate the association between disease progression rate, use of non-invasive ventilation, and survival in patients with partial ventilatory support
(access to NIV without respiratory physiotherapy assistance) during a
three-year follow-up. Methods: This was a longitudinal, retrospective,
single-center observational study in which individuals undergoing periodic
respiratory assessments at the Laboratory of the Federal University of Rio
Grande do Norte, Northeast Brazil, were followed from December 2022 to
December 2025. Individuals eligible for ventilatory support met the
standardized clinical criteria in the literature. Expected Results: It is likely that
the majority of the sample will consist of male individuals with spinal onset of
the disease, followed by bulbar and respiratory phenotypes, as evidenced in
the literature. It is estimated that most patients will require NIV in the final
stage of the disease, with an average predicted start date of approximately 24
months after the onset of symptoms. Cox proportional hazards regression
analysis is projected to identify a higher risk of death in patients with rapid
disease progression, while the use of NIV is associated with better survival. It
is also expected that individuals with rapid progression will have a higher risk
of death compared to those with slow progression, while the use of NIV will
demonstrate a protective effect, with a significant reduction in this risk. Even
when initiated late, approximately two years after the onset of the disease, NIV
is expected to be associated with increased survival, reinforcing its relevance
in the clinical management of ALS patients, especially in the context of
multidisciplinary follow-up and periodic respiratory support.

 

 

COMMITTEE MEMBERS:
Externa à Instituição - ANA CRISTINA DE MEDEIROS GARCIA MACIEL
Presidente - 1545315 - GUILHERME AUGUSTO DE FREITAS FREGONEZI
Interna - 2211046 - LUCIEN PERONI GUALDI